Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hillestad draws FDA warning

This article was originally published in The Tan Sheet

Executive Summary

Woodruff, Wisc.-based Hillestad Pharmaceuticals is violating a 2000 consent decree by making unapproved drug claims for its dietary supplement products, FDA says in Oct. 1 "Talk Paper." The agency told the firm in a letter it may face a contempt proceeding if it does not cease claims made in promotional materials identified during a recent inspection. FDA "also directs the firm to pay liquidated damages in the amount of $23,000, which reflects sales of Opti-Cran, Hi-C Level, ginkgo biloba and St. John's wort that were made in violation of the court order." The consent decree was part of a settlement of an FDA/Department of Justice case against Hillestad for marketing unapproved new drugs...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS097355

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel